EP Patent

EP4637749A2 — Cbl-b modulators and uses thereof

Assigned to Nimbus Clio Inc · Expires 2025-10-29 · 1y expired

What this patent protects

The present invention provides compounds of formula I-III, compositions thereof, and methods of using the same for the inhibition of Cbl-b, and the treatment of Cbl-b-mediated disorders.

USPTO Abstract

The present invention provides compounds of formula I-III, compositions thereof, and methods of using the same for the inhibition of Cbl-b, and the treatment of Cbl-b-mediated disorders.

Drugs covered by this patent

Patent Metadata

Patent number
EP4637749A2
Jurisdiction
EP
Classification
—
Expires
2025-10-29
Drug substance claim
No
Drug product claim
No
Assignee
Nimbus Clio Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.